Salmeterol

Generic Name: Salmeterol

Brand Names: Advair, Airduo, Airduo Respiclick, Serevent, Serevent Diskus, Wixela

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₇NO_₄

CAS Number: 89365-50-4

Unique Ingredient Identifier: 2I4BC502BT

Background: Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD. It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, salbutamol. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine.

Salmeterol was granted FDA approval on 4 February 1994.

Indication: 用于哮喘（包括夜间哮喘和运动性哮喘）、喘息性支气管炎和可逆性气道阻塞。

Associated Conditions: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm

Clinical Trials

An Evaluation of the Safety and Efficacy of LIPO-102 for the Reduction of Subcutaneous Abdominal Adiposity

Phase 2

Completed

Conditions: Subcutaneous Abdominal Adiposity

Interventions: Drug: LIPO-102
Drug: Placebo

First Posted Date: 2010-03-31

Last Posted Date: 2015-03-26

Lead Sponsor: Neothetics, Inc

Target Recruit Count: 60

Registration Number: NCT01096979

Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Salmeterol 50 μg
Drug: Placebo to indacaterol
Drug: Indacaterol
Drug: Placebo to salmeterol

First Posted Date: 2010-03-18

Last Posted Date: 2011-08-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 552

Registration Number: NCT01089127

Locations: 🇺🇸
Novartis Investigative Site, Richmond, Virginia, United States
🇺🇸
Novartis Investigator Site, Tacoma, Washington, United States
🇺🇸
Novartis Investigative site, Newport News, Virginia, United States

Efficacy and Safety of Different Doses of Indacaterol

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Placebo to Indacaterol
Drug: Indacaterol
Drug: Salmeterol
Drug: Placebo to Salmeterol

First Posted Date: 2010-03-02

Last Posted Date: 2011-08-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 511

Registration Number: NCT01079130

Locations: 🇺🇸
Novartis Investigative site, North Charleston, South Carolina, United States
🇺🇸
Novartis Investigator Site, Seattle, Washington, United States
🇺🇸
Novartis Investigative Site, Charleston, South Carolina, United States

Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler®

Phase 2

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Formoterol
Drug: Salmeterol
Drug: Placebo

First Posted Date: 2010-01-13

Last Posted Date: 2012-10-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 109

Registration Number: NCT01048333

Locations: 🇸🇪
Research Site, Lund, Sweden

Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Fluticasone propionate/salmeterol combination product
Drug: Salmeterol
Drug: Placebo

First Posted Date: 2009-09-25

Last Posted Date: 2018-08-29

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 366

Registration Number: NCT00984659

Locations: 🇺🇸
GSK Investigational Site, Spokane, Washington, United States

Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: tiotropium inhalation
Drug: salmeterol xinafoate
Drug: fluticasone propionate
Drug: placebo matched for fluticasone propionate

First Posted Date: 2009-09-11

Last Posted Date: 2015-02-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2488

Registration Number: NCT00975195

Locations: 🇭🇺
352.2046.36004 Boehringer Ingelheim Investigational Site, Komarom, Hungary
🇭🇺
352.2046.36001 Boehringer Ingelheim Investigational Site, Szarvas, Hungary
🇭🇺
352.2046.36006 Boehringer Ingelheim Investigational Site, Pecs, Hungary

and more 219 locations